Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 6 |
| List of Tables | 5 | 2 |
| List of Figures | 7 | 2 |
| Gout Therapeutics Market: Introduction | 9 | 1 |
| GBI Research Report Guidance | 9 | 1 |
| Gout Therapeutics Market: Market Overview | 10 | 11 |
| Introduction | 10 | 1 |
| Disease Overview | 10 | 1 |
| Progression Stages | 10 | 1 |
| Epidemiology | 10 | 1 |
| Symptoms | 10 | 1 |
| Diagnosis | 11 | 1 |
| Treatment | 11 | 1 |
| Global Market Overview | 12 | 1 |
| Revenue Forecasts for the Global Gout Therapeutics Market | 12 | 1 |
| Revenue | 12 | 2 |
| Annual Cost of Treatment (ACT) | 14 | 1 |
| Treatment Usage Patterns | 15 | 2 |
| Diseased Population | 17 | 1 |
| Treatment Seeking Population | 18 | 1 |
| Diagnosed Population | 19 | 1 |
| Prescription Population | 20 | 1 |
| Gout Therapeutics Market: Geographic Landscape | 21 | 36 |
| Revenue Analysis by Geography | 21 | 2 |
| The US | 23 | 1 |
| Revenue | 23 | 1 |
| Annual Cost of Treatment (ACT) | 24 | 1 |
| Treatment Usage Patterns | 25 | 2 |
| Diseased Population | 27 | 1 |
| Treatment Seeking Population | 28 | 1 |
| Diagnosed Population | 29 | 1 |
| Prescription Population | 30 | 1 |
| Top Five Countries of Europe | 31 | 1 |
| Revenue | 31 | 1 |
| Annual Cost of Treatment (ACT) | 32 | 1 |
| Treatment Usage Patterns | 33 | 2 |
| Diseased Population | 35 | 1 |
| Treatment Seeking Population | 36 | 1 |
| Diagnosed Population | 37 | 1 |
| Prescription Population | 38 | 1 |
| The UK | 39 | 1 |
| Revenue | 39 | 1 |
| Prescription Population | 40 | 1 |
| Germany | 41 | 1 |
| Revenue | 41 | 1 |
| Prescription Population | 42 | 1 |
| France | 43 | 1 |
| Revenue | 43 | 1 |
| Prescription Population | 44 | 1 |
| Italy | 45 | 1 |
| Revenue | 45 | 1 |
| Prescription Population | 46 | 1 |
| Spain | 47 | 1 |
| Revenue | 47 | 1 |
| Prescription Population | 48 | 1 |
| Japan | 49 | 1 |
| Revenue | 49 | 1 |
| Annual Cost of Treatment (ACT) | 50 | 1 |
| Treatment Usage Patterns | 51 | 2 |
| Diseased Population | 53 | 1 |
| Treatment Seeking Population | 54 | 1 |
| Diagnosed Population | 55 | 1 |
| Prescription Population | 56 | 1 |
| Gout Therapeutics Market: Therapeutic Landscape | 57 | 28 |
| Gout Therapeutics Market for Acute Gout | 57 | 1 |
| Introduction | 57 | 1 |
| Revenue | 57 | 2 |
| Revenue Analysis by Geography | 59 | 2 |
| Annual Cost of Treatment | 61 | 1 |
| Annual Cost of Treatment by Geography | 62 | 2 |
| Treatment Usage Patterns | 64 | 2 |
| Disease Population | 66 | 1 |
| Treatment Seeking Population | 67 | 1 |
| Diagnosed Population | 68 | 1 |
| Prescription Population | 69 | 1 |
| Gout Therapeutics Market for Chronic Gout | 70 | 1 |
| Introduction | 70 | 1 |
| Revenue | 70 | 2 |
| Revenue Analysis by Geography | 72 | 2 |
| Annual Cost of Treatment | 74 | 1 |
| Annual Cost of Treatment by Geography | 75 | 2 |
| Treatment Usage Patterns | 77 | 2 |
| Diseased Population | 79 | 1 |
| Treatment Seeking Population | 80 | 1 |
| Diagnosed Population | 81 | 1 |
| Prescription Population | 82 | 1 |
| Drivers and Barriers to the Gout Therapeutics Market | 83 | 1 |
| Drivers to the Gout Therapeutics Market | 83 | 1 |
| Expected Launch of New Drugs will Drive the Gout Therapeutics Market | 83 | 1 |
| Limited Number of Approved Therapies will Create Concentrated Patient Pools | 83 | 1 |
| Increasing Prevalence and Diagnosis will Drive the Gout Therapeutics Market | 83 | 1 |
| Barriers to the Gout Therapeutics Market | 84 | 1 |
| Lower Treatment Seeking Rate Could Prevent the Gout Therapeutics Market from Achieving Higher Growth | 84 | 1 |
| Low Patient Affordability for Biologics could Affect the Growth in the Future | 84 | 1 |
| Gout Therapeutics Market: Product Pipeline Analysis | 85 | 4 |
| Introduction | 85 | 1 |
| Research and Development Pipeline | 85 | 1 |
| Overview | 85 | 1 |
| Pipeline by Clinical Phases of Development | 86 | 1 |
| Gout Therapeutics Discovery Product Pipeline | 86 | 1 |
| Gout Therapeutics Preclinical Product Pipeline | 86 | 1 |
| Gout Therapeutics Investigational New Drug (IND) Filed | 86 | 1 |
| Gout Therapeutics Phase I Product Pipeline | 86 | 1 |
| Gout Therapeutics Phase II Product Pipeline | 87 | 1 |
| Gout Therapeutics Phase III Product Pipeline | 87 | 1 |
| Profiles of Promising Drugs in the Gout Therapeutics Market | 88 | 1 |
| ACZ885 | 88 | 1 |
| Overview | 88 | 1 |
| Mechanism of Action | 88 | 1 |
| Arcalyst | 88 | 1 |
| Overview | 88 | 1 |
| Mechanism of Action | 88 | 1 |
| Gout Therapeutics Market: Company Profiles | 89 | 5 |
| Takeda Pharmaceutical Company Limited | 89 | 1 |
| Company Overview | 89 | 1 |
| SWOT Analysis | 89 | 1 |
| Savient Pharmaceuticals, Inc. | 90 | 1 |
| Company Overview | 90 | 1 |
| SWOT Analysis | 90 | 1 |
| Novartis AG | 91 | 1 |
| Company Overview | 91 | 1 |
| SWOT Analysis | 91 | 1 |
| Regeneron Pharmaceuticals, Inc. | 92 | 1 |
| Company Overview | 92 | 1 |
| SWOT Analysis | 92 | 1 |
| Teijin Pharma Limited | 93 | 1 |
| Company Overview | 93 | 1 |
| SWOT Analysis | 93 | 1 |
| Gout Therapeutics Market: Strategic Consolidations | 94 | 9 |
| Overview | 94 | 1 |
| Mergers and Acquisitions | 95 | 1 |
| Major M&A Deals (2004-2010) | 95 | 1 |
| Deal Summary | 96 | 1 |
| Hi-Tech Pharmacal Acquires Licensing Rights of Naprelan from Stat-Trade | 96 | 1 |
| BioPhausia Acquires Pharmaceutical Products Portfolio from AstraZeneca | 96 | 1 |
| Polaris Acquires Intellectual Property Rights of Uricase-PEG 20 from Phoenix Pharmacologics | 96 | 1 |
| Strides Arcolab Acquires Drug Houses of Australia from Haw Par Healthcare | 96 | 1 |
| Hi-Tech Pharmacal and Stat-Trade Sell Rights of Naprelan to Victory Pharma | 96 | 1 |
| EnzymeRx Acquires Uricase-PEG 20 from Polaris Pharmaceuticals | 96 | 1 |
| Is Private Equity Acquires 17% Stake in Frik Ilac | 97 | 1 |
| 3SBio Acquires Rights of Pegsiticase from EnzymeRx | 97 | 1 |
| Norgine Acquires 12.6% Stake in ProStrakan | 97 | 1 |
| Deals by Deal Value | 97 | 1 |
| Deals by Geography | 98 | 1 |
| Deals by Type | 99 | 1 |
| Licensing Agreements | 100 | 1 |
| Major Licensing Deals | 100 | 1 |
| Deal Summary | 100 | 1 |
| Teijin Pharma Enters into Licensing Agreement with Astellas Pharma Taiwan | 100 | 1 |
| Teijin Pharma Enters into Licensing Agreement with Menarini | 100 | 1 |
| Menarini Enters into Licensing Agreement with Ipsen | 100 | 1 |
| FAES Farma Enters into Licensing Agreement with Merck Sharp &Dohme | 101 | 1 |
| Teijin Pharma Enters into an Agreement with Astellas Pharma | 101 | 1 |
| XOMA Enters into Licensing Agreement with Les Laboratoires Servier for XOMA 052 | 101 | 1 |
| Deals by Geography | 102 | 1 |
| Gout Therapeutics Market: Appendix | 103 | 6 |
| Market Definitions | 103 | 1 |
| Abbreviations | 103 | 1 |
| Research Methodology | 104 | 5 |
| Coverage | 104 | 1 |
| Primary Research | 105 | 1 |
| Forecasts | 105 | 1 |
| Epidemiology-based Forecasting | 105 | 3 |
| Expert Panel Validation | 108 | 1 |
| Contact Us | 108 | 1 |
| Disclaimer | 108 | 1 |
| Sources | 108 | 1 |